Clinical Trial Update: A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating XZP-3287 in combination with Fulvestrant for advanced breast cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• XZP-3287

Snippet

Sponsor: Xuanzhu Biopharmaceutical Co., Ltd. | Conditions: Advanced Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING